<

LAXXON MEDICAL Laxxon Medical to Participate in 23rd Annual Needham Virtual Health Conference

Transparency directive : regulatory news

28/03/2024 13:00

Laxxon Medical to Participate in 23rd Annual Needham Virtual Health Conference

New York, 03/28/2024 / 08:00, EST/EDT - EQS Newswire - Laxxon Medical


NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Laxxon Medical, a leading pharma-technology company pioneering a new generation of advanced pharmaceuticals, announced today their participation as a private company in the 23rd Annual Needham Virtual Healthcare Conference on April 8-11, 2024.

Helmut Kerschbaumer, CEO/Chairman, and Alexander Ruckdaeschel, Chief Strategy Officer, will hold one-on-one meetings with institutional, private equity, and venture capital investors from April 8-11, 2024.

The fully virtual conference will feature fireside chats and presentations from leading public and private companies in the Biopharma, Medtech, Diagnostics and Digital Health sectors as well as thematic panel discussions.

About Laxxon Medical
Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients.

Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims.

Company website: www.laxxonmedical.com.

Investor Contact:
Alexander Ruckdaeschel
Chief Strategy Director
alexander.ruckdaeschel@laxxonmedical.com

Media Contact:
Frances Hoggard
Communications Manager
frances.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical



03/28/2024 EQS Newswire / EQS Group AG



fncls.ssp?fn=show_t_gif&application_id=1869285&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6


Other stories

27/04/2024 06:01
27/04/2024 10:39
27/04/2024 12:45
27/04/2024 10:04
27/04/2024 10:45
27/04/2024 02:45
27/04/2024 11:33
27/04/2024 04:35
26/04/2024 12:15
27/04/2024 09:28
26/04/2024 23:49
27/04/2024 04:51
26/04/2024 18:24
27/04/2024 03:13
26/04/2024 18:00
26/04/2024 23:01
27/04/2024 00:36
26/04/2024 14:07
27/04/2024 01:21
27/04/2024 08:30
27/04/2024 08:30
27/04/2024 02:40
27/04/2024 10:16
27/04/2024 08:10
27/04/2024 05:31
26/04/2024 22:02
27/04/2024 09:58
27/04/2024 08:31
27/04/2024 12:32
27/04/2024 11:00
27/04/2024 01:12
26/04/2024 20:00
25/04/2024 13:31
25/04/2024 21:00
26/04/2024 23:47
26/04/2024 10:48
26/04/2024 03:31
26/04/2024 22:00